Recombinant Growth Hormone Therapy in Children with GH Deficiency: First Interventional Study in Armenia

Abstract

Objectives: Effective management of diabetes is the cornerstone for prevention of diabetic complications. However, how well the Finnish Current Care guideline for diabetes is implemented in practice is unknown. Combining local and nationwide patient registers provide a valuable resource for evaluating risks, benefits and costs. The purpose of this study was to identify how the Finnish electronic patient information systems and national registers can be used to explore the treatment for patients with incident type 2 diabetes. MethOds: Selected primary and specialty care organizations representing different geographical areas and patient information system providers were invited to participate in the study. Study permits were obtained from several local and nationwide register holders. The study protocol was reviewed by the Ethical Review Board of Hospital District of Helsinki and Uusimaa. Results: Register linkage is accomplished using unique personal identification numbers. We collect nationwide data on prescriptions, hospital and primary care, reimbursed dental care, and the causes of death. Cost data are based on hospital benchmarking database, sickness allowances and rehabilitations. We use local registers as a source of information on diagnoses, medical procedures, prescriptions and contact types. High quality laboratory data are also included from several local providers. cOnclusiOns: Register linkages enable longitudinal follow-up of patients for research purposes in Finland. In our study a unique combined register database of diabetic patient cohort is created that improves the evaluation of prognosis and care of diabetic patients. This is a promising and versatile source for research in pharmacoepidemiology. PDB28 ePiDemiology anD Unmet meDical neeD in DiaBetes mellitUs tyPe 2 in germany -resUlts of a literatUre search

Alteraciones metabólicas en niños con deficiencia de hormona de crecimiento

“…Un aumento de las cifras de triglicéridos y disminución de las LDL tras un año de tratamiento fue notificado por Witkouska-Sedek et al 34 Algunos estudios no encontraron cambios significativos en el perfil lipídico después de 12 meses de tratamiento. 6,17,36,46 La mayoría de los estudios 8,18,28,37,47,43 al comparar los niños con DGH con niños sanos señalan un perfil lipídico desfavorable en los primeros. En algunas investigaciones 17,36 no se detectan diferencias.…”